Fuso Pharmaceutical IndustriesFuso Pharmaceutical Industries,Ltd.4538東証プライム医薬品FY ending Mar 2026, non-consolidated, J-GAAP
Fuso Pharmaceutical Industries brought in ¥62.3B in revenue.
Out of every ¥100 of sales, about ¥4 is left as operating profit.
Revenue changed +2.9% from the prior year, operating profit -36.1%.
Revenue +2.9% · profit -36.1%, calculated from disclosed figures.
Operating leverage: -12.54× (profit growth ÷ revenue growth)
FY ending Mar 2025 → FY ending Mar 2026
FY ending Mar 2025 → FY ending Mar 2026
For every ¥100 Fuso Pharmaceutical Industries sells, how much goes where, and how much is kept.
Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.
EDINET (FSA Japan)
有価証券報告書－第103期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
有価証券報告書－第102期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
有価証券報告書－第101期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
有価証券報告書－第100期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
有価証券報告書－第99期(令和3年4月1日－令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書－第98期(令和2年4月1日－令和3年3月31日)
Extracted from XBRL: 50 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.